Granulocyte-macrophage colony stimulating factor treatment of febrile neutropenia following remission induction chemotherapy for acute leukemia.
Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF) was given for 2-6 days in 10 patients with febrile neutropenias following remission induction chemotherapy for acute leukemia (6 acute lymphoblastic and 4 acute myeloid leukemias) in which, broad spectrum and targeted antibiotherapy was ineffective. In 7 patients, the addition of GM-CSF helped overcome the serious infectious complications, leading to an accelerated neutrophil recovery averaging 18.4 days, significantly faster than in a historic group of 9 similar patients in whom GM-CSF was not given Side-effects of GM-CSF treatment were minor and reversible. GM-CSF treatment did not have any significant effect on the achievement of complete remission status.
Cucuianu
A
A
Oncological Institute, Malignant Hemopathies Department, Cluj-Napoca, Romania.
Petrov
L
L
Ghiurt
A
A
Vasilache
A
A
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009503:Neutropenia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D009504:Neutrophils / Q000187:drug effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D011994:Recombinant Proteins; D012074:Remission Induction
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor